Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]
Zhongguo quanke yixueBackground Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj +1 more source
Clinical Cardiology, Volume 47, Issue 1, January 2024.Hypertrophic cardiomyopathy (HCM) is an increasingly recognized genetic condition that is accompanied by a heterogeneous phenotype. The presence of outflow tract obstruction carries an increased risk for the development of heart failure, arrhythmias, and sudden cardiac death.
Mariem A. Sawan +6 more
wiley +1 more source
Hypertrophic Cardiomyopathy: Current Perspectives
Reviews in Cardiovascular MedicineHypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel +3 more
doaj +1 more source
Treatment options for hypertrophic obstructive cardiomyopathy in the era of myosin inhibitors
Frontiers in Cardiovascular MedicineHypertrophic obstructive cardiomyopathy (HOCM) is characterised by left ventricular outflow tract obstruction (LVOTO) caused by septal hypertrophy and its interaction with the mitral valve and systolic anterior motion.
Chukwunenyem Nwuba +2 more
doaj +1 more source
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
International audienceHypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM.
Edell, Samantha +19 more
core +1 more source
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Head-to-Head Network Meta-Analysis of Mavacamten and Aficamten [PDF]
Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypercontractility. Mavacamten and aficamten are first-in-class cardiac myosin inhibitors that have demonstrated efficacy in treating obstructive HCM. However,
Imran Saleh +4 more
core +1 more source
Monaldi Archives for Chest DiseasePediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio +7 more
doaj +1 more source
Amorphous Form of Aficamten and Its preparation process
This publication relates to amorphous form of Aficamten (I) and process for its ...
Anonymous
core +1 more source
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy
Journal of Cardiovascular Development and DiseaseThe management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi +9 more
doaj +1 more source
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy [PDF]
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and ...
Lee, Matthew M.Y. +22 more
core +1 more source